Clinical Trial Update: A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A combined Phase 1/2 trial evaluated nab-paclitaxel and gemcitabine with or without the angiogenesis-targeting antibody olaratumab in metastatic pancreatic canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Olaratumab (olaratumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-01-11